Risk factors for hepatic decompensation in patients with primary biliary cirrhosis

World Journal of Gastroenterology

Volumn 19, Issue 7, 2013, Pages 1111-1118

  Shi, Tian Yan ^a   Zhang, Li Na ^a   Chen, Hua ^a   Wang, Li ^a   Shen, Min ^a   Zhang, Xuan ^a   Zhang, Feng Chun ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Anti centromere antibodies; Hepatic decompensation; Histological stage; Primary biliary cirrhosis; Risk factor; Survival; Ursodeoxycholic acid response

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN; CENTROMERE ANTIBODY; MITOCHONDRION ANTIBODY;

ADULT; AGED; ARTICLE; DEATH; DECOMPENSATED LIVER CIRRHOSIS; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INCIDENCE; LIVER BIOPSY; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIMARY BILIARY CIRRHOSIS; PROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE;

EID: 84874391247     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i7.1111     Document Type: Article

References (53)

1. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353: 1261-1273. [PMID: 16177252 DOI: 10.1056/ NEJMra043898]
2. Prince MI, James OF. The epidemiology of primary biliary cirrhosis. Clin Liver Dis 2003; 7: 795-819. [PMID: 14594132]
3. Lazaridis KN, Talwalkar JA. Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy. J Clin Gastroenterol 2007; 41: 494-500. [PMID: 17450033 DOI:10.1097/01.mcg.0000225653.07932.8f]
4. Ishibashi H, Komori A, Shimoda S, Ambrosini YM, Gershwin ME, Nakamura M. Risk factors and prediction of longterm outcome in primary biliary cirrhosis. Intern Med 2011; 50: 1-10. [PMID: 21212566]
5. Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol 2010; 52: 745-758. [PMID: 20347176]
6. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10: 1-7. [PMID: 2737595]
7. Grambsch PM, Dickson ER, Wiesner RH, Langworthy A. Application of the Mayo primary biliary cirrhosis survival model to Mayo liver transplant patients. Mayo Clin Proc 1989; 64: 699-704. [PMID: 2664365]
8. Mayo MJ, Parkes J, Adams-Huet B, Combes B, Mills AS, Markin RS, Rubin R, Wheeler D, Contos M, West AB, Saldana S, Getachew Y, Butsch R, Luketic V, Peters M, Di Bisceglie A, Bass N, Lake J, Boyer T, Martinez E, Boyer J, Garcia-Tsao G, Barnes D, Rosenberg WM. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 2008; 48: 1549-1557. [PMID: 18846542 DOI: 10.1002/hep.22517]
9. Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, Houben MH, Witteman BJ, van Erpecum KJ, van Buuren HR. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009; 136: 1281-1287. [PMID: 19208346 DOI: 10.1053/ j.gastro.2009.01.003]
10. Gao L, Tian X, Liu B, Zhang F. The value of antinuclear antibodies in primary biliary cirrhosis. Clin Exp Med 2008; 8: 9-15. [PMID: 18385935]
11. Su CW, Hung HH, Huo TI, Huang YH, Li CP, Lin HC, Lee PC, Lee SD, Wu JC. Natural history and prognostic factors of primary biliary cirrhosis in Taiwan: a follow-up study up to 18 years. Liver Int 2008; 28: 1305-1313. [PMID: 18346129 DOI: 10.1111/j.1478-3231.2008.01715.x]
12. Zhao DT, Liao HY, Liu YM, Zhao Y, Feng X, Yan HP. Prognostic factors and survival analysis of antimitochondrial antibody-positive primary biliary cirrhosis in Chinese patients. Dig Dis Sci 2011; 56: 2750-2757. [PMID: 21409375 DOI: 10.1007/s10620-011-1661-7]
13. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978; 379: 103-112. [PMID: 150690]
14. Chazouillères O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28: 296-301. [PMID: 9695990 DOI: 10.1002/hep.510280203]
15. Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006; 130: 715-720. [PMID: 16530513 DOI: 10.1053/j.gastro.2005.12.029]
16. Murray-Lyon IM, Pugh RN, Nunnerley HB, Laws JW, Dawson JL, Williams R. Treatment of bleeding oesophageal varices by infusion of vasopressin into the superior mesenteric artery. Gut 1973; 14: 59-63. [PMID: 4540294]
17. Farrell GC. Primary biliary cirrhosis in Asians: less common than in Europeans, but just as depressing. J Gastroenterol Hepatol 2008; 23: 508-511. [PMID: 18397481 DOI: 10.1111/j.1440-1746.2008.05379.x]
18. Liu H, Liu Y, Wang L, Xu D, Lin B, Zhong R, Gong S, Podda M, Invernizzi P. Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China. BMC Gastroenterol 2010; 10: 100. [PMID: 20815889 DOI: 10.1186/1471-230X-10-100]
19. Hohenester S, Oude-Elferink RP, Beuers U. Primary biliary cirrhosis. Semin Immunopathol 2009; 31: 283-307. [PMID: 19603170 DOI: 10.1007/s00281-009-0164-5]
20. Marasini B, Gagetta M, Rossi V, Ferrari P. Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients. Ann Rheum Dis 2001; 60: 1046-1049. [PMID: 11602476]
21. Silveira MG, Mendes FD, Diehl NN, Enders FT, Lindor KD. Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease. Liver Int 2009; 29: 1094-1100. [PMID: 19291181 DOI: 10.1111/ j.1478-3231.2009.02003.x]
22. Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002; 123: 1044-1051. [PMID:12360466]
23. Prince MI, Chetwynd A, Craig WL, Metcalf JV, James OF. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 2004; 53: 865-870. [PMID: 15138215]
24. Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. Lancet 2011; 377: 1600-1609. [PMID: 21529926]
25. Milkiewicz P, Heathcote EJ. Fatigue in chronic cholestasis. Gut 2004; 53: 475-477. [PMID: 15016736]
26. Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 1994; 20: 707-713. [PMID: 7930469]
27. Springer J, Cauch-Dudek K, O'Rourke K, Wanless IR, Heathcote EJ. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol 1999; 94: 47-53. [PMID: 9934730 DOI: 10.1111/j.1572-0241.1999.00770.x]
28. Floreani A, Caroli D, Variola A, Rizzotto ER, Antoniazzi S, Chiaramonte M, Cazzagon N, Brombin C, Salmaso L, Baldo V. A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre. Liver Int 2011; 31: 361-368. [PMID: 21059170 DOI: 10.1111/j.1478-3231.2010. 02366.x]
29. Baldursdottir TR, Bergmann OM, Jonasson JG, Ludviksson BR, Axelsson TA, Björnsson ES. The epidemiology and natural history of primary biliary cirrhosis: a nationwide population-based study. Eur J Gastroenterol Hepatol 2012; 24: 824-830. [PMID: 22562114 DOI: 10.1097/MEG.0b013e328353753d]
30. Ngu JH, Gearry RB, Frampton CM, Stedman CA. Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. Hepatology 2012; 55: 522-529. [PMID: 21994151 DOI: 10.1002/ hep.24743]
31. Myers RP, Shaheen AA, Fong A, Burak KW, Wan A, Swain MG, Hilsden RJ, Sutherland L, Quan H. Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a population-based study. Hepatology 2009; 50: 1884-1892. [PMID: 19821525 DOI: 10.1002/hep.23210]
32. Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999; 29: 644-647. [PMID: 10051462 DOI: 10.1002/hep. 510290301]
33. Corpechot C, Carrat F, Bahr A, Chrétien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005; 128: 297-303. [PMID: 15685541]
34. Poupon RE, Lindor KD, Parés A, Chazouillères O, Poupon R, Heathcote EJ. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003; 39: 12-16. [PMID: 12821038]
35. Corpechot C, Abenavoli L, Rabahi N, Chrétien Y, Andréani T, Johanet C, Chazouillères O, Poupon R. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008; 48: 871-877. [PMID: 18752324 DOI: 10.1002/hep.22428]
36. Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y. Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatol 2005; 32: 1488-1494. [PMID: 16078324]
37. Salliot C, Gottenberg JE, Bengoufa D, Desmoulins F, MiceliRichard C, Mariette X. Anticentromere antibodies identify patients with Sjögren's syndrome and autoimmune overlap syndrome. J Rheumatol 2007. 34: 2253-2258. [PMID: 17937465]
38. Hossny E, Hady HA, Mabrouk R. Anti-centromere anti-bodies as a marker of Raynaud's phenomenon in pediatric rheumatologic diseases. Pediatr Allergy Immunol 2000; 11: 250-255. [PMID: 11110581]
39. Takada K, Suzuki K, Matsumoto M, Okada M, Nakanishi T, Horikoshi H, Higuchi T, Ohsuzu F. Clinical characteristics of patients with both anti-U1RNP and anti-centromere antibodies. Scand J Rheumatol 2008; 37: 360-364. [PMID: 18686191 DOI: 10.1080/03009740802116190]
40. Pakozdi A, Nihtyanova S, Moinzadeh P, Ong VH, Black CM, Denton CP. Clinical and serological hallmarks of systemic sclerosis overlap syndromes. J Rheumatol 2011; 38: 2406-2409. [PMID: 21844148 DOI: 10.3899/jrheum.101248]
41. Agmon-Levin N, Shapira Y, Selmi C, Barzilai O, Ram M, Szyper-Kravitz M, Sella S, Katz BS, Youinou P, Renaudineau Y, Larida B, Invernizzi P, Gershwin ME, Shoenfeld Y. A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. J Autoimmun 2010; 34: 55-58. [PMID: 19897339 DOI: 10.1016/j.jaut.2009.08.009]
42. Muratori P, Muratori L, Ferrari R, Cassani F, Bianchi G, Lenzi M, Rodrigo L, Linares A, Fuentes D, Bianchi FB. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003; 98: 431-437. [PMID: 12591064]
43. Granito A, Muratori P, Muratori L, Pappas G, Cassani F, Worthington J, Ferri S, Quarneti C, Cipriano V, de Molo C, Lenzi M, Chapman RW, Bianchi FB. Antibodies to SS-A/Ro52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. Aliment Pharmacol Ther 2007; 26: 831-838. [PMID: 17767467 DOI: 10.1111/j.1365-2036.2007.03433.x]
44. Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, Takii Y, Koyabu M, Yokoyama T, Migita K, Daikoku M, Abiru S, Yatsuhashi H, Takezaki E, Masaki N, Sugi K, Honda K, Adachi H, Nishi H, Watanabe Y, Nakamura Y, Shimada M, Komatsu T, Saito A, Saoshiro T, Harada H, Sodeyama T, Hayashi S, Masumoto A, Sando T, Yamamoto T, Sakai H, Kobayashi M, Muro T, Koga M, Shums Z, Norman GL, Ishibashi H. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007; 45: 118-127. [PMID: 17187436 DOI: 10.1002/hep.21472]
45. Yang WH, Yu JH, Nakajima A, Neuberg D, Lindor K, Bloch DB. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? Clin Gastroenterol Hepatol 2004; 2: 1116-1122. [PMID: 15625657]
46. Rigamonti C, Shand LM, Feudjo M, Bunn CC, Black CM, Denton CP, Burroughs AK. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 2006; 55: 388-394. [PMID: 16150855 DOI: 10.1136/ gut.2005.075002]
47. Parveen S, Morshed SA, Nishioka M. High prevalence of antibodies to recombinant CENP-B in primary biliary cirrhosis: nuclear immunofluorescence patterns and ELISA reactivities. J Gastroenterol Hepatol 1995; 10: 438-445. [PMID: 8527711]
48. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, Weinman SA. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366-375. [PMID: 11832451]
49. Su CW, Chan CC, Hung HH, Huo TI, Huang YH, Li CP, Lin HC, Tsay SH, Lee PC, Lee SD, Wu JC. Predictive value of aspartate aminotransferase to alanine aminotransferase ratio for hepatic fibrosis and clinical adverse outcomes in patients with primary biliary cirrhosis. J Clin Gastroenterol 2009; 43: 876-883. [PMID: 19247208 DOI: 10.1097/ MCG.0b013e31818980ac]
50. Garrido MC, Hubscher SG. Accuracy of staging in primary biliary cirrhosis. J Clin Pathol 1996; 49: 556-559. [PMID: 8813953]
51. Drebber U, Mueller JJ, Klein E, Kasper HU, Schulze F, Schardt K, Quasdorff M, Schulte S, Odenthal M, Dienes HP. Liver biopsy in primary biliary cirrhosis: clinicopathological data and stage. Pathol Int 2009; 59: 546-554. [PMID: 19627538 DOI: 10.1111/j.1440-1827.2009.02405.x]
52. Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 1983; 308: 1-7. [PMID: 6847917 DOI: 10.1056/NEJM198301063080101]
53. Locke GR, Therneau TM, Ludwig J, Dickson ER, Lindor KD. Time course of histological progression in primary biliary cirrhosis. Hepatology 1996; 23: 52-56. [PMID: 8550048 DOI: 10.1002/hep.510230108]